Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement - Royalty Pharma ( NASDAQ:RPRX ) , Ascendis Pharma ( NASDAQ:ASND )
COPENHAGEN, Denmark and NEW YORK, Sept. 03, 2024 ( GLOBE NEWSWIRE ) -- Ascendis Pharma A/S ASND and Royalty Pharma plc RPRX today announced that Ascendis Pharma Bone Diseases A/S, a wholly-owned subsidiary of Ascendis Pharma A/S, has entered into a $150 million capped synthetic royalty funding ...
| Ticker |
Sentiment |
Impact |
|
ASND
|
Somewhat Bullish
|
12 %
|
|
RPRX
|
Somewhat Bullish
|
32 %
|
|
ABBV
|
Neutral
|
2 %
|
